文献速递临床试验与 GCP

经导管主动脉瓣植入术与外科主动脉瓣置换术对主动脉瓣狭窄患者全因死亡率的影响:一项随机临床试验

Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

这项在英国34个中心开展的随机临床试验纳入913例70岁及以上、因年龄或合并症导致手术风险中度增加的严重症状性主动脉瓣狭窄患者,比较经导管主动脉瓣植入术(TAVI)与外科主动脉瓣置换术。1年时TAVI组死亡21例(4.6%),手术组死亡30例(6.6%),校正绝对风险差为-2.0%(单侧97.5%CI,-∞至1.2%;非劣效性P<.001),TAVI不劣于手术。

要点

  • 在手术风险中度增加的严重症状性主动脉瓣狭窄患者中,TAVI在1年全因死亡率方面不劣于外科主动脉瓣置换术。
  • TAVI组术后住院中位时间3天,短于手术组的8天。
  • TAVI组大出血事件更少,但血管并发症、需起搏器植入的传导障碍及主动脉瓣反流更多。

核心结论

  • 在70岁及以上、因年龄或合并症导致手术风险中度增加的严重症状性主动脉瓣狭窄患者中,TAVI在1年全因死亡率方面不劣于外科主动脉瓣置换术。

研究设计与样本

  • 随机临床试验,在英国34个中心开展,2014年4月至2018年4月入组,随访至2019年4月。
  • 共纳入913例70岁及以上、严重症状性主动脉瓣狭窄且因年龄或合并症导致手术风险中度增加的患者。
  • TAVI组458例,使用任何带CE标志的瓣膜及任何入路;外科主动脉瓣置换术组455例。
  • 主要结局为1年全因死亡率,非劣效性界值为组间死亡率绝对差单侧97.5%CI上限5%。

主要发现

  • 912例(99.9%)完成随访并纳入非劣效性分析;中位年龄81岁(IQR 78至84岁),女性424例(46%),胸外科医师学会死亡风险评分中位数2.6%(IQR 2.0%至3.4%)。
  • 1年时TAVI组死亡21例(4.6%),手术组死亡30例(6.6%),校正绝对风险差-2.0%(单侧97.5%CI,-∞至1.2%;非劣效性P<.001)。
  • 预设的30个次要结局中,24个在1年时无显著差异。
  • TAVI组术后住院中位时间3天(IQR 2至5天),手术组8天(IQR 6至13天)。
  • 1年时TAVI组较手术组大出血事件显著更少(7.2% vs 20.2%;校正HR 0.33,95%CI 0.24至0.45),但血管并发症(10.3% vs 2.4%;校正HR 4.42,95%CI 2.54至7.71)、需起搏器植入的传导障碍(14.2% vs 7.3%;校正HR 2.05,95%CI 1.43至2.94)及轻度(38.3% vs 11.7%)或中度(2.3% vs 0.6%)主动脉瓣反流显著更多;轻度、中度或重度(原文报告无重度病例)主动脉瓣反流合并与无主动脉瓣反流相比的校正OR为4.89(95%CI 3.08至7.75)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transcatheter aortic valve implantation (TAVI) is a less invasive alternative to surgical aortic valve replacement and is the treatment of choice for patients at high operative risk. The role of TAVI in patients at lower risk is unclear. OBJECTIVE: To determine whether TAVI is noninferior to surgery in patients at moderately increased operative risk. DESIGN, SETTING, AND PARTICIPANTS: In this randomized clinical trial conducted at 34 UK centers, 913 patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk due to age or comorbidity were enrolled between April 2014 and April 2018 and followed up through April 2019. INTERVENTIONS: TAVI using any valve with a CE mark (indicating conformity of the valve with all legal and safety requirements for sale throughout the European Economic Area) and any access route (n = 458) or surgical aortic valve replacement (surgery; n = 455). MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality at 1 year. The primary hypothesis was that TAVI was noninferior to surgery, with a noninferiority margin of 5% for the upper limit of the 1-sided 97.5% CI for the absolute between-group difference in mortality. There were 36 secondary outcomes (30 reported herein), including duration of hospital stay, major bleeding events, vascular complications, conduction disturbance requiring pacemaker implantation, and aortic regurgitation. RESULTS: Among 913 patients randomized (median age, 81 years [IQR, 78 to 84 years]; 424 [46%] were female; median Society of Thoracic Surgeons mortality risk score, 2.6% [IQR, 2.0% to 3.4%]), 912 (99.9%) completed follow-up and were included in the noninferiority analysis. At 1 year, there were 21 deaths (4.6%) in the TAVI group and 30 deaths (6.6%) in the surgery group, with an adjusted absolute risk difference of -2.0% (1-sided 97.5% CI, -∞ to 1.2%; P < .001 for noninferiority). Of 30 prespecified secondary outcomes reported herein, 24 showed no significant difference at 1 year. TAVI was associated with significantly shorter postprocedural hospitalization (median of 3 days [IQR, 2 to 5 days] vs 8 days [IQR, 6 to 13 days] in the surgery group). At 1 year, there were significantly fewer major bleeding events after TAVI compared with surgery (7.2% vs 20.2%, respectively; adjusted hazard ratio [HR], 0.33 [95% CI, 0.24 to 0.45]) but significantly more vascular complications (10.3% vs 2.4%; adjusted HR, 4.42 [95% CI, 2.54 to 7.71]), conduction disturbances requiring pacemaker implantation (14.2% vs 7.3%; adjusted HR, 2.05 [95% CI, 1.43 to 2.94]), and mild (38.3% vs 11.7%) or moderate (2.3% vs 0.6%) aortic regurgitation (adjusted odds ratio for mild, moderate, or severe [no instance of severe reported] aortic regurgitation combined vs none, 4.89 [95% CI, 3.08 to 7.75]). CONCLUSIONS AND RELEVANCE: Among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk, TAVI was noninferior to surgery with respect to all-cause mortality at 1 year. TRIAL REGISTRATION: isrctn.com Identifier: ISRCTN57819173.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Toff WD, Hildick-Smith D, Kovac J, et al. Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial. JAMA. 2022. PMID: 35579641. doi:10.1001/jama.2022.5776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。